P&G management changes
This article was originally published in The Rose Sheet
Executive Summary
Cosmetics VP Marc Pritchard promoted to VP-global cosmetics and personal care, assuming responsibility for global personal cleansing, deodorants in addition to existing responsibility for Cover Girl and Max Factor, Procter & Gamble announces. Appointment is effective July 1. Paolo de Cesare, currently VP-Northeast Asia skin care and cosmetics, appointed VP-global prestige beauty and skin care, taking on responsibility for P&G's global fine fragrances and mass skin care brands, including Olay, while continuing to oversee SKII brand. Execs will report to President-Global Personal Beauty Care Susan Arnold, who will assume added leadership of global feminine care business...
You may also be interested in...
P&G names four presidents
VPs Marc Pritchard and Paolo de Cesare promoted to president of their respective divisions in recognition of their strong leadership contribution, P&G announces July 25. Pritchard oversees global cosmetics and personal care, while de Cesare directs global prestige beauty and skin care. Two additional execs also were promoted to president from current VP roles - Michael Kehoe, who oversees global oral care, and Martin Riant, who heads global feminine care. Presidential posts are new positions that will be effective Sept. 1. Pritchard and de Cesare were appointed to their current roles last year (1"The Rose Sheet" April 29, 2002, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.